Jinlong Ding, Ph.D.’s Post

HER2 negative Breast Cancer Pipeline Report (2024): Analysis of Clinical Trials, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

🔬 Did you know pharmacogenomics (PGx) testing is revolutionizing cancer care? By personalizing treatments based on genetics, PGx is helping patients and providers make more informed, effective decisions. Learn how this groundbreaking science is shaping the future of oncology. 👉 Read more: https://lnkd.in/eHPAqsMw #Pharmacogenomics #CancerCare #PrecisionMedicine #PGx #HealthcareInnovation

IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Excited to share the publication of our systematic review “Targeting BCL-2 Family Proteins Using BH3 Mimetic Drugs for Cancer Therapy: A Systematic Review of Randomized Clinical Trials.” This study rigorously analyzes clinical trial data to assess the safety and effectiveness BH3 mimetic drugs in malignancies. A big thank you to Mohammad Ashrafuzzaman and Fatimah Alharbi for their support and contribution. Evidence-based research is essential in advancing medicine and patient outcomes. https://lnkd.in/dAzyxb_9 #Science #Medicine #Cancer #Oncology #ClinicalTrials

Anti- CEACAM6 antibody+ BET protein degrader conjugate inhibits tumour growth in pancreatic cancer models. https://lnkd.in/g43BaqPm

$AZN TRuQAP combo treatment for prostate cancer has shown promising results in clinical trials. The combination therapy could potentially offer a significant advancement in treatment options for patients: https://ibn.fm/jcxAf #AstraZeneca #TRuQAP #CancerTreatment #Oncology

Invion Limited (ASX:IVX) innovative INV043 therapy has shown promising results in a Phase II clinical trial for prostate cancer, offering a potential alternative to conventional treatments. With a strong safety profile and 40% positive response rate, INV043 could provide a safer path forward for patients. Key highlights: 💊 40% of patients showed a positive response, with 10% achieving complete regression. 💊 44% of patients had negative PSMA-PET results three months post-treatment. 💊 No serious adverse events reported. Thian Chew, Executive Chair and CEO, commented: “These results show that INV043 can be safely administered and activated with light to treat prostate cancer, without the devastating side effects associated with conventional treatments.” Alan Yamashita Alistair Bennallack Melanie Leydin CA FGIA #ProstateCancer #CancerTreatment #Biotech #MedicalInnovation #INV043 #ClinicalTrials #ASX

#AntibodyDrugConjugates Continue to Transform the Oncology Landscape 👇 Targeted Oncology discuss how #ADCs are a revolutionary class of targeted cancer therapies that deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Click the link below to read the article 🔗 https://t.co/rlBMUC9kxm

Unlocking the potential of #antibodydrugconjugates 👇 Drug Target Review discuss how advancements in #ADCs are redefining cancer treatment. Click the link below to read the article 🔗 https://lnkd.in/ecVhiuqp

Early data suggests that bispecific antibody petosemtamab, in conjunction with Keytruda, generates a 60% response rate in patients with second-line head and neck cancer. However, more mature clinical data will give us a clearer picture of how accurate this is. Get in touch to discover how evitria can support your antibody needs. #Biotech #BispecificAntibodies #Antibodies #HeadAndNeckCancer